Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1212.5 | 52 | |
| RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 2054.0 | 48 | |
| N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 465.0 | 65 | |
| N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1008.0 | 50 | |
| RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1187.0 | 47 | |
| RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1720.0 | 49 | |
| N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1558.0 | 56 | |
| N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 3406.0 | 49 | |
| RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 8987.5 | 54 | |
| RA1869 | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 9155.5 | 54 | ||||
| N2759 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 8181.5 | 38 | |
| N2759 | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 8641.5 | 38 | ||||
| RA1931 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 7021.0 | 39 | |
| RA1931 | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 5379.0 | 49 | ||||
| N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 9055.5 | 46 | |
| N2586 | TNF-a | 100 | ng/mL | 1 | MCP-1 (MCAF) | 9234.0 | 55 | ||||
| RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 75.5 | 38 | |
| RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 614.5 | 58 | |
| N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 100.0 | 59 | |
| N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1012.0 | 53 | |
| RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 143.0 | 48 | |
| RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 757.0 | 35 | |
| N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 361.5 | 48 | |
| N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 1764.5 | 44 | |
| RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP-1 (MCAF) | 7697.0 | 48 |